Expert Insights on Oncology
Oncology is the field of medicine dealing with tumors (cancer), including their biology, prevention, diagnosis, and treatment. Cancer biology focuses on the mechanisms for abnormal cell growth and tumor metastasis; diagnosis involves biopsy, endoscopy, radiological imaging, nuclear medicine, and blood tests for tumor markers; prevention includes genetic testing, education, and screening; therapies like surgery, chemotherapy, and radiation therapy aim to inhibit tumor development.
Gerson Lehrman Group Council Members are available to discuss Oncology via phone consultations, live meetings, surveys, and other custom GLG products and services.
Find, engage, and manageSM experts today through the GLG platform
Featured Council Members
GLG Council Members are leading experts including academics, scientists, and industry specialists
-
Taral Patel, MD
OncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC
-
Charles Bennett, M.D.
Radiation Oncologist ROBERT BOISSONEAULT ONCOLOGY INSTITUTE
-
Brian Abbott, MD
Medical Director of HematologyBig Sky Oncology
-
Jon Strasser, MD
Assistant Professor of Radiation OncologyTHOMAS JEFFERSON UNIVERSITY
-
Donald Fleming, MD
Division Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC
Study Groups
Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry
| Study Group Name | No. Members |
|---|---|
| Oncology Devices Distributors | 25 |
| Oncology Reimbursement Experts (US) | 111 |
| Oncology Physicians who Treat CID (US) | 22 |
| Radiologists who Perform IMRT | 21 |
| Tykerb Prescribers (US) | 22 |
Recent Live Meetings
Interactive roundtables, private visits, and small scale seminars are types of GLG Live Meetings
-
November 20, 2009 | New York
Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD -
November 12, 2009 | Boston
Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD (Boston) -
November 13, 2009 | New York
Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD (New York)
Recent News Analyses
News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations
-
ASTRO/ACRO help win the fight against Reimbursement Cuts for Radiation Oncology
November 2, 2009
CMS announcement regarding Radiation Oncology Reimbursement for 2010 | cs.astro.org
Major news breaking.. CMS has decided to implement only a 1% cut annually for radiation oncology reimbursement. This may be the most important news item in the world of oncology for the past decade. Faced with untenable projected cut of 19%, CMS reversed course and reduced the reduction in paym...
-
Particle Beam Technology - Costly and a limited utility
October 26, 2009
Jon Strasser, MD, Assistant Professor of Radiation Oncology, THOMAS JEFFERSON UNIVERSITY
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly...
-
Triple negative Breast Cancer Strategies
October 14, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...
-
Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we...
-
Herceptin for Her2 + gastric cancer, If you can find one
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com
Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer